联环药业：关于控股子公司药品通过仿制药一致性评价的公告

Core Points - The company Lianhuan Pharmaceutical announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplemental application of Eszopiclone tablets, confirming that the product meets the consistency evaluation of quality and efficacy for generic drugs [2] Group 1 - Lianhuan Pharmaceutical's subsidiary has successfully passed the consistency evaluation for its generic drug [2] - The approval is significant for the company's product portfolio and market positioning in the pharmaceutical industry [2]